Wilms tumor and the WT1 gene.

Wilms tumor or nephroblastoma is a pediatric kidney cancer arising from pluripotent embryonic renal precursors. Multiple genetic loci have been linked to Wilms tumorigenesis; positional cloning strategies have led to the identification of the WT1 tumor suppressor gene at chromosome 11p13. WT1 encodes a zinc finger transcription factor that is inactivated in the germline of children with genetic predisposition to Wilms tumor and in a subset of sporadic cancers. When present in the germline, specific heterozygous dominant-negative mutations are associated with severe abnormalities of renal and sexual differentiation, pointing to the essential role of WT1 for normal genitourinary development. The role of this tumor suppressor in normal organ-specific differentiation is also supported by the highly restricted temporal and spatial expression of WT1 in glomerular precursors of the developing kidney and by the failure of kidney development in wt1-null mice. Of two major alternative splicing products encoded by WT1, the (-KTS) isoform appears to mediate transcriptional activation of genes implicated in cellular differentiation, possibly also repressing proliferation-associated genes. The (+KTS) isoform, whose DNA-binding domain is disrupted by the insertion of three amino acids, may be involved in some aspect of mRNA processing. In addition to its function in genitourinary development, a role for WT1 in hematopoiesis is suggested by its aberrant expression and/or mutation in a subset of acute human leukemias. WT1 is also expressed in mesothelial cells; a specific oncogenic chromosomal translocation fusing the N-terminal domain of the Ewing sarcoma gene EWS to the three C-terminal zinc fingers of WT1 underlies desmoplastic small round cell tumor, an abdominal tumor thought to arise from the peritoneal lining. Understanding the distinct functional properties of WT1 isoforms and tumor-associated variants will provide unique insight into the link between normal organ-specific differentiation and malignancy.

[1]  F. Rauscher,et al.  The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  J. Licht,et al.  WT1-mediated Transcriptional Activation Is Inhibited by Dominant Negative Mutant Proteins (*) , 1995, The Journal of Biological Chemistry.

[3]  H. Tojo,et al.  Wilms' tumor suppressor gene (WT1) as a target gene of SRY function in a mouse ES cell line transfected with SRY. , 1998, The International journal of developmental biology.

[4]  B. Williams,et al.  Homozygous somatic Wt1 point mutations in sporadic unilateral Wilms tumor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  B. Lampkin,et al.  Chromosome analysis of 31 Wilms' tumors. , 1990, Cancer research.

[6]  D. D. Mosser,et al.  The DNA-binding activity of the human heat shock transcription factor is regulated in vivo by hsp70 , 1993, Molecular and cellular biology.

[7]  G. Saunders,et al.  Expression of the Wilms' tumor gene (WT1) in human leukemias. , 1992, Leukemia.

[8]  H. Zinszner,et al.  A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. , 1994, Genes & development.

[9]  G. Thomas,et al.  EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts , 1993, Nature Genetics.

[10]  J. Licht,et al.  The Transcriptional Effect of WT1 Is Modulated by Choice of Expression Vector (*) , 1995, The Journal of Biological Chemistry.

[11]  N. Nowak,et al.  Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations , 1994, Nature Genetics.

[12]  S. Sukumar,et al.  RNA editing in the Wilms' tumor susceptibility gene, WT1. , 1994, Genes & development.

[13]  Z. Wang,et al.  Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways. , 1995, Oncogene.

[14]  J. Bard,et al.  The candidate Wilms' tumour gene is involved in genitourinary development , 1990, Nature.

[15]  Eileen D. Adamson,et al.  A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization , 1988, Cell.

[16]  J. Pelletier,et al.  The DNA binding domains of the WT1 tumor suppressor gene product and chimeric EWS/WT1 oncoprotein are functionally distinct , 1998, Oncogene.

[17]  H. DeLuca,et al.  The Wilms' Tumor Gene Product (WT1) Modulates the Response to 1,25-Dihydroxyvitamin D3 by Induction of the Vitamin D Receptor* , 2001, The Journal of Biological Chemistry.

[18]  T. Ekström,et al.  IGF2 is parentally imprinted during human embryogenesis and in the Beckwith–Wiedemann syndrome , 1993, Nature Genetics.

[19]  Y. Yazaki,et al.  Loss of WT1 function leads to ectopic myogenesis in Wilms' tumour , 1998, Nature Genetics.

[20]  D. Housman,et al.  Expression of the Wilms' tumor gene WT1 in the murine urogenital system. , 1991, Genes & development.

[21]  D. Housman,et al.  Sequence and structural requirements for high-affinity DNA binding by the WT1 gene product , 1995, Molecular and cellular biology.

[22]  Y. Wu,et al.  GATA-1 Transactivates the WT1 Hematopoietic Specific Enhancer (*) , 1995, The Journal of Biological Chemistry.

[23]  Marc Fellous,et al.  Donor splice-site mutations in WT1 are responsible for Frasier syndrome , 1997, Nature Genetics.

[24]  K. Worley,et al.  A dosage sensitive locus at chromosome Xp21 is involved in male to female sex reversal , 1994, Nature Genetics.

[25]  Beckwith Jb.  New developments in the pathology of Wilms tumor. , 1997 .

[26]  D. Housman,et al.  Wilms' tumor protein WT1 as an ovarian transcription factor: decreases in expression during follicle development and repression of inhibin-alpha gene promoter. , 1995, Molecular endocrinology.

[27]  G. Lenoir,et al.  Are bilateral tumours hereditary? , 1991, International journal of epidemiology.

[28]  J. Pelletier,et al.  The desmoplastic small round cell tumor t(11;22) translocation produces EWS/WT1 isoforms with differing oncogenic properties , 1998, Oncogene.

[29]  S. Korsmeyer,et al.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair , 1993, Cell.

[30]  G. Saunders,et al.  Transactivation of an Intronic Hematopoietic-specific Enhancer of the Human Wilms’ Tumor 1 Gene by GATA-1 and c-Myb* , 1997, The Journal of Biological Chemistry.

[31]  W. Gerald,et al.  The Wilms Tumor Suppressor WT1 Encodes a Transcriptional Activator of amphiregulin , 1999, Cell.

[32]  C. Ware,et al.  Mesenchymal to Epithelial Conversion in Rat Metanephros Is Induced by LIF , 1999, Cell.

[33]  David Housman,et al.  WT-1 is required for early kidney development , 1993, Cell.

[34]  S M Hewitt,et al.  Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. , 1995, Cancer research.

[35]  B. Williams,et al.  Identification of Connective Tissue Growth Factor as a Target of WT1 Transcriptional Regulation* , 2000, The Journal of Biological Chemistry.

[36]  N. Tommerup,et al.  Ciao 1 Is a Novel WD40 Protein That Interacts with the Tumor Suppressor Protein WT1* , 1998, The Journal of Biological Chemistry.

[37]  P Scambler,et al.  Frasier syndrome is caused by defective alternative splicing of WT1 leading to an altered ratio of WT1 +/-KTS splice isoforms. , 1998, Human molecular genetics.

[38]  Z. Wang,et al.  The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. , 1993, The Journal of biological chemistry.

[39]  A. Jochemsen,et al.  Physical Interaction between Wilms Tumor 1 and p73 Proteins Modulates Their Functions* , 2000, The Journal of Biological Chemistry.

[40]  P. Sorensen,et al.  A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS–family transcription factor, ERG , 1994, Nature Genetics.

[41]  K. Tadokoro,et al.  A novel mutation of the WT1 gene (a tumor suppressor gene for Wilms' tumor) in a patient with Denys-Drash syndrome. , 1993, Human molecular genetics.

[42]  D. Bonthron,et al.  Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[43]  K. Miyagawa,et al.  Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies , 1999, Genes, chromosomes & cancer.

[44]  T. Kudoh,et al.  Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. , 1996, Blood.

[45]  K. Imai,et al.  Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. , 1994, Blood.

[46]  D. Housman,et al.  Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome. , 1992, Oncogene.

[47]  A. Brookes,et al.  A zinc finger truncation of murine WT1 results in the characteristic urogenital abnormalities of Denys-Drash syndrome. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  G. Saunders,et al.  PAX 8 Regulates Human WT1 Transcription through a Novel DNA Binding Site* , 1997, The Journal of Biological Chemistry.

[49]  S. Elledge,et al.  Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome , 1997, Nature.

[50]  P. Sharp,et al.  A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Sukumar,et al.  A rodent model for Wilms tumors: embryonal kidney neoplasms induced by N-nitroso-N'-methylurea. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Patil,et al.  Abnormality of chromosome 11 in patients with features of Beckwith-Wiedemann syndrome. , 1983, The Journal of pediatrics.

[53]  J. Fraumeni,et al.  ASSOCIATION OF WILMS'S TUMOR WITH ANIRIDIA, HEMIHYPERTROPHY AND OTHER CONGENITAL MALFORMATIONS. , 1964, The New England journal of medicine.

[54]  A. Hagemeijer,et al.  Expression of the wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet‐derived growth factor A and insulin‐like growth factor 2 expression , 1995, Genes, chromosomes & cancer.

[55]  K. Malik,et al.  Autoregulation of the human WT1 gene promoter , 1994, FEBS letters.

[56]  G. Heinze,et al.  Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia , 1998, Leukemia.

[57]  D. Housman,et al.  A mouse model of the aniridia-Wilms tumor deletion syndrome. , 1990, Science.

[58]  P. Scambler,et al.  Loss of heterozygosity for the short arm of chromosome 7 in sporadic Wilms tumour , 1998, Oncogene.

[59]  R. Weksberg,et al.  Disruption of insulin–like growth factor 2 imprinting in Beckwith–Wiedemann syndrome , 1993, Nature genetics.

[60]  J. Pelletier,et al.  The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1). , 1996, Oncogene.

[61]  N. Breslow,et al.  Constitutional WT1 mutations in Wilms' tumor patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  J. Pelletier,et al.  PAX8‐mediated activation of the wt1 tumor suppressor gene. , 1996, The EMBO journal.

[63]  Amy Bernard,et al.  Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour , 1993, Nature Genetics.

[64]  D. Housman,et al.  Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus , 1990, Cell.

[65]  G. Elgar,et al.  Complete sequencing of the Fugu WAGR region from WT1 to PAX6: dramatic compaction and conservation of synteny with human chromosome 11p13. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[66]  J. Pelletier,et al.  Overlapping RNA and DNA binding domains of the wt1 tumor suppressor gene product. , 1998, Nucleic acids research.

[67]  High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome , 1997 .

[68]  T. Akiyama,et al.  Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1). , 1996, Oncogene.

[69]  M. von Knebel Doeberitz,et al.  Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. , 1999, Cancer research.

[70]  K. Miyagawa,et al.  Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing , 1995, Cell.

[71]  J. Bennington,et al.  Tumours of the Kidney, Renal Pelvis and Ureter , 1979 .

[72]  E. Thiel,et al.  Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. , 1995, Leukemia.

[73]  C. Junien,et al.  Uniparental paternal disomy in a genetic cancer-predisposing syndrome , 1991, Nature.

[74]  T. Mukai,et al.  Genomic imprinting of p57KIP2, a cyclin–dependent kinase inhibitor, in mouse , 1995, Nature Genetics.

[75]  D. Housman,et al.  Alternative splicing and genomic structure of the Wilms tumor gene WT1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[76]  C. Cooper,et al.  Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma. , 1996, Oncogene.

[77]  D. Housman,et al.  Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development , 1991, Molecular and cellular biology.

[78]  G. Johnson,et al.  Expression of the Wilms' tumor suppressor gene, WT1, is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells. , 1998, Blood.

[79]  L. Ercolani,et al.  LLC-PK1 Cell Growth Is Repressed by WT1 Inhibition of G-protein αi−2 Protooncogene Transcription (*) , 1995, The Journal of Biological Chemistry.

[80]  M. Bartolomei,et al.  Parental imprinting of the mouse H19 gene , 1991, Nature.

[81]  N D Hastie,et al.  Presence of WT1, the Wilm's Tumor Suppressor Gene Product, in Nuclear Poly(A)+ Ribonucleoprotein* , 1999, The Journal of Biological Chemistry.

[82]  A. Feinberg,et al.  Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[83]  M. Eccles,et al.  Constitutional relaxation of insulin–like growth factor II gene imprinting associated with Wilms' tumour and gigantism , 1993, Nature Genetics.

[84]  Nazneen Rahman,et al.  Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12–q21 , 1996, Nature Genetics.

[85]  M. Eccles,et al.  Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour , 1993, Nature.

[86]  W. Gerald,et al.  Case 2. Desmoplastic small cell tumor with divergent differentiation. , 1989, Pediatric pathology.

[87]  N. Breslow,et al.  Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. , 1994, Cancer research.

[88]  D. Housman,et al.  Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. , 1991, American journal of human genetics.

[89]  C. Disteche,et al.  The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity , 1990, Molecular and cellular biology.

[90]  D. Haber,et al.  Induction of p21 by the Wilms' tumor suppressor gene WT1. , 1997, Cancer research.

[91]  J. Pelletier,et al.  WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion. , 1994, Genomics.

[92]  P. Baird,et al.  Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. , 1997, Experimental hematology.

[93]  T. Akiyama,et al.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.

[94]  U. Maurer,et al.  The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. , 1997, Experimental hematology.

[95]  D. Haber,et al.  E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells , 1998, Oncogene.

[96]  K. Tadokoro,et al.  Exon 9 mutations in the WT1 gene, without influencing KTS splice isoforms, are also responsible for Frasier syndrome , 1999, Human mutation.

[97]  H. Werner,et al.  Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression , 1995, Molecular and cellular biology.

[98]  R. Jaenisch,et al.  Initial differentiation of the metanephric mesenchyme is independent of WT1 and the ureteric bud. , 1999, Developmental genetics.

[99]  T. Akiyama,et al.  Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apoptotic cell death in response to retinoic acid. , 1996, Oncogene.

[100]  G. Plowman,et al.  Structure and function of human amphiregulin: a member of the epidermal growth factor family. , 1989, Science.

[101]  D. Morris,et al.  Ornithine decarboxylase is a transcriptional target of tumor suppressor WT1. , 1999, Experimental cell research.

[102]  N. Nowak,et al.  Fine structure analysis of the WT1 gene in sporadic Wilms tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[103]  G I Bell,et al.  Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. , 1992, Science.

[104]  M. Brand,et al.  Zebrafish no isthmus reveals a role for pax2.1 in tubule differentiation and patterning events in the pronephric primordia. , 2000, Development.

[105]  L. Boxer,et al.  The WT1 Protein Is a Negative Regulator of the Normalbcl-2 Allele in t(14;18) Lymphomas* , 1997, The Journal of Biological Chemistry.

[106]  A. Feinberg,et al.  Relaxation of imprinted genes in human cancer , 1993, Nature.

[107]  J. Pelletier,et al.  Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. , 1995, Oncogene.

[108]  S. Orkin,et al.  Development of homozygosity for chromosome 11p markers in Wilms' tumour , 1984, Nature.

[109]  P. Sharpe,et al.  The evolution of WT1 sequence and expression pattern in the vertebrates. , 1995, Oncogene.

[110]  Benjamin Tycko,et al.  Tumour-suppressor activity of H19 RNA , 1993, Nature.

[111]  A. Feinberg,et al.  Somatic deletion and duplication of genes on chromosome 11 in Wilms' tumours , 1984, Nature.

[112]  T. Akiyama,et al.  G1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[113]  A. Feinberg,et al.  Genetic linkage of Beckwith-Wiedemann syndrome to 11p15. , 1989, American journal of human genetics.

[114]  J. Pelletier,et al.  A Non-AUG Translational Initiation Event Generates Novel WT1 Isoforms (*) , 1996, The Journal of Biological Chemistry.

[115]  K. Semba,et al.  cDNA cloning and its pronephros-specific expression of the Wilms' tumor suppressor gene, WT1, from Xenopus laevis. , 1996, Gene.

[116]  E. Torban,et al.  Effects of PAX2 expression in a human fetal kidney (HEK293) cell line. , 1998, Biochimica et biophysica acta.

[117]  T. Hunter,et al.  Inhibition of the DNA-binding and transcriptional repression activity of the Wilms' tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain , 1997, Oncogene.

[118]  B. Perbal,et al.  Regulation of nov by WT1: a potential role for nov in nephrogenesis. , 1996, Oncogene.

[119]  T. Akiyama,et al.  The Wilms tumor suppressor gene WT1 induces G1 arrest and apoptosis in myeloblastic leukemia M1 cells , 1997, FEBS letters.

[120]  Amy Bernard,et al.  The Wilms tumour gene WT1 is expressed in murine mesoderm–derived tissues and mutated in a human mesothelioma , 1993, Nature Genetics.

[121]  C. Denny,et al.  The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1 , 1993, Molecular and cellular biology.

[122]  N. Mandahl,et al.  Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma , 1993, Nature.

[123]  Y. Fukushima,et al.  An imprinted gene p57KIP2 is mutated in Beckwith–Wiedemann syndrome , 1996, Nature Genetics.

[124]  M. Vidal,et al.  Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[125]  P. Smith,et al.  A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. , 1996, Oncogene.

[126]  R. Morimoto,et al.  Activation of Heat Shock Factor 1 DNA Binding Precedes Stress-induced Serine Phosphorylation , 1996, The Journal of Biological Chemistry.

[127]  H. Cunliffe,et al.  Differential regulation of the human Wilms tumour suppressor gene (WT1) promoter by two isoforms of PAX2 , 1997, Oncogene.

[128]  J. Testa,et al.  Molecular Cloning of the cDNA and Chromosome Localization of the Gene for Human Ubiquitin-conjugating Enzyme 9* , 1996, The Journal of Biological Chemistry.

[129]  A. Lamond,et al.  WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. , 1998, Genes & development.

[130]  J. Licht,et al.  A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1 , 1996, Molecular and cellular biology.

[131]  D. Housman,et al.  WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour , 1991, Nature.

[132]  U. Francke,et al.  Aniridia-Wilms' tumor association: evidence for specific deletion of 11p13. , 1979, Cytogenetics and cell genetics.

[133]  D. Housman,et al.  Antagonism of WT1 activity by protein self-association. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[134]  A. Schedl,et al.  Cross-talk in kidney development. , 2000, Current opinion in genetics & development.

[135]  J. Licht,et al.  Tumor-associated WT1 Missense Mutants Indicate That Transcriptional Activation by WT1 Is Critical for Growth Control* , 1999, The Journal of Biological Chemistry.

[136]  K. Pritchard-Jones,et al.  Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. , 1998, Blood.

[137]  D. Housman,et al.  Germline intronic and exonic mutations in the Wilms' tumour gene (WT1) affecting urogenital development , 1992, Nature Genetics.

[138]  A. Jochemsen,et al.  Wilms' tumor 1-KTS isoforms induce p53-independent apoptosis that can be partially rescued by expression of the epidermal growth factor receptor or the insulin receptor. , 1997, Cancer research.

[139]  A. Poustka,et al.  Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping , 1990, Nature.

[140]  Zhaoyi Wang,et al.  Induction of Rb-associated Protein (RbAp46) by Wilms’ Tumor Suppressor WT1 Mediates Growth Inhibition* , 1998, The Journal of Biological Chemistry.

[141]  H. Menssen,et al.  Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. , 1997, Blood.

[142]  S. Madden,et al.  Transcriptional repression mediated by the WT1 Wilms tumor gene product. , 1991, Science.

[143]  A. J. Mcadams,et al.  Multifocal nephroblastic neoplasia. , 1978, Journal of the National Cancer Institute.

[144]  J. Bard,et al.  The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo , 1993, Mechanisms of Development.

[145]  Y. Oji,et al.  Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. , 1998, Blood.

[146]  J. Pelletier,et al.  The Wilms’ Tumor Suppressor Gene (wt1) Product Regulates Dax-1 Gene Expression during Gonadal Differentiation , 1999, Molecular and Cellular Biology.

[147]  A. Chitale,et al.  Rat renal mesenchymal tumor as an experimental model for human congenital mesoblastic nephroma: II. Comparative pathology. , 1989, Pediatric pathology.

[148]  M. Gessler,et al.  Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlates with clinicopathological parameters , 1998, Genes, chromosomes & cancer.

[149]  K. Pritchard-Jones,et al.  Mutations in the Wilms' tumor gene WT1 in leukemias. , 1996, Blood.

[150]  Bruce Futcher,et al.  Role of a ubiquitin-conjugating enzyme in degradation of S- and M-phase cyclins , 1995, Nature.

[151]  S. Hewitt,et al.  Differential Function of Wilms Tumor Gene WT1 Splice Isoforms in Transcriptional Regulation (*) , 1996, The Journal of Biological Chemistry.

[152]  V. Sukhatme,et al.  Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[153]  J. Morris,et al.  Repression of Pax-2 by WT1 during normal kidney development. , 1995, Development.

[154]  J. Beckwith.  Macroglossia, omphalocele, adrenal cytomegaly, gigantism, and hyperplastic visceromegaly , 1969 .

[155]  D. Haber,et al.  WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. , 1993, Science.

[156]  S. Vainio,et al.  Inductive Tissue Interactions, Cell Signaling, and the Control of Kidney Organogenesis , 1997, Cell.

[157]  M. Ouchida,et al.  The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. , 1994, Oncogene.

[158]  J. Morris,et al.  Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. , 1995, The American journal of pathology.

[159]  M. Bernfield,et al.  Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. , 1996, Oncogene.

[160]  W. Bickmore,et al.  Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript. , 1992, Science.

[161]  S. Mundlos,et al.  Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. , 1993, Development.

[162]  J. Licht,et al.  E-cadherin Is a WT1 Target Gene* , 2000, The Journal of Biological Chemistry.

[163]  A. Gurney,et al.  Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. , 1996, The EMBO journal.

[164]  H. Sugiyama,et al.  Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia. , 1998, Leukemia & lymphoma.

[165]  U. Francke,et al.  Chromosomal imbalance in the Aniridia-Wilms' tumor association: 11p interstitial deletion. , 1978, Pediatrics.

[166]  Y. Ohaki.  Renal tumors induced transplacentally in the rat by n-ethylnitrosourea. , 1989, Pediatric pathology.

[167]  K. Call,et al.  Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[168]  T. Curran,et al.  Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. , 1990, Science.

[169]  M. Gessler,et al.  Analysis of WT1 target gene expression in stably transfected cell lines , 1998, Oncogene.

[170]  D. Loh,et al.  Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[171]  P. D. Vize,et al.  Wilms' tumor suppressor gene is involved in the development of disparate kidney forms: Evidence from expression in the Xenopus Pronephros , 1996, Developmental dynamics : an official publication of the American Association of Anatomists.

[172]  W. Gerald,et al.  The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour , 1997, Nature Genetics.

[173]  C. Denny,et al.  A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. , 1995, Oncogene.

[174]  V. Sukhatme,et al.  DNA recognition by splicing variants of the Wilms' tumor suppressor, WT1 , 1994, Molecular and cellular biology.

[175]  P. Telzerow,et al.  Chromosome 11 uniparental isodisomy predisposing to embryonal neoplasms , 1991, The Lancet.

[176]  H. Werner,et al.  The IGF-I Receptor Gene Promoter Is a Molecular Target for the Ewing's Sarcoma-Wilms' Tumor 1 Fusion Protein* , 1996, The Journal of Biological Chemistry.

[177]  H. Pass,et al.  Wilms' tumor suppressor gene expression in rat and human mesothelioma. , 1994, Cancer research.

[178]  D. Housman,et al.  Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome , 1991, Cell.

[179]  J. Pelletier,et al.  Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product , 1996, FEBS letters.

[180]  C. McCoy,et al.  The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[181]  M. Cleary,et al.  Oppositely imprinted genes p57(Kip2) and igf2 interact in a mouse model for Beckwith-Wiedemann syndrome. , 1999, Genes & development.

[182]  M. Höglund,et al.  Fusion of the EWS and CHOP genes in myxoid liposarcoma. , 1996, Oncogene.

[183]  W. Gerald,et al.  Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[184]  M. Down,et al.  Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice. , 2000, Cancer research.

[185]  D. Housman,et al.  Structural rearrangements of the WT1 gene in Wilms' tumour cells. , 1991, Oncogene.

[186]  P. Berry,et al.  Inactivation of the remaining allele of the WT1 gene in a Wilms' tumour from a WAGR patient. , 1992, Oncogene.

[187]  A. Reeve,et al.  Loss of allelic heterozygosity at a second locus on chromosome 11 in sporadic Wilms' tumor cells , 1989, Molecular and cellular biology.

[188]  W. Gerald,et al.  Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[189]  N D Hastie,et al.  RNA binding by the Wilms tumor suppressor zinc finger proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[190]  W. Cavenee,et al.  Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. , 1989, American journal of human genetics.

[191]  P. Smith,et al.  Zinc finger point mutations within the WT1 gene in Wilms tumor patients. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[192]  L. Strong,et al.  Positional cloning and characterization of a paired box- and homeobox-containing gene from the aniridia region , 1991, Cell.

[193]  J. Licht,et al.  The tumor suppressor gene WT1 inhibits ras-mediated transformation. , 1995, Oncogene.

[194]  Harlan I. Firminger,et al.  Atlas of tumor pathology , 1954 .

[195]  C. Y. Wang,et al.  WT1 modulates apoptosis by transcriptionally upregulating the bcl‐2 proto‐oncogene , 1999, The EMBO journal.

[196]  S. Madden,et al.  The Wilms' tumor suppressor gene WT1 is negatively autoregulated. , 1994, The Journal of biological chemistry.

[197]  P. Gruss,et al.  Pax2, a new murine paired-box-containing gene and its expression in the developing excretory system. , 1990, Development.

[198]  L. Saxén,et al.  Epithelial-mesenchymal interactions regulate the stage-specific expression of a cell surface proteoglycan, syndecan, in the developing kidney. , 1989, Developmental biology.

[199]  A. Feinberg,et al.  A third Wilms' tumor locus on chromosome 16q. , 1992, Cancer research.

[200]  N. Copeland,et al.  Loss of alleles at loci on human chromosome 11 during genesis of Wilms' tumour , 1984, Nature.

[201]  Amy Bernard,et al.  Physical and functional interaction between WT1 and p53 proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[202]  A. McMahon,et al.  Wnt-4 is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney. , 1998, Development.

[203]  R. Ezzell,et al.  Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70. , 1998, Genes & development.

[204]  V. Sukhatme,et al.  Sp1 Is a Critical Regulator of the Wilms' tumor-1 Gene* , 1997, The Journal of Biological Chemistry.

[205]  D. Haber,et al.  WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. , 1995, The EMBO journal.

[206]  C. Englert,et al.  The Wilms tumor suppressor gene wt1 is required for development of the spleen , 1999, Current Biology.

[207]  D. Haber,et al.  WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. , 1995, Cancer research.

[208]  W. Gerald,et al.  Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. , 1994, Cancer research.

[209]  Z. Wang,et al.  Wilms' tumor gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain. , 1999, Biochemical and biophysical research communications.

[210]  A. Schedl,et al.  YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. , 1999, Development.

[211]  N. Kiviat,et al.  Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. , 1990, Pediatric pathology.

[212]  Z. Wang,et al.  A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[213]  J. Mattick,et al.  An RNA recognition motif in Wilms' tumour protein (WT1) revealed by structural modelling , 1996, Nature Genetics.

[214]  P. Chambon,et al.  hTAF(II)68, a novel RNA/ssDNA‐binding protein with homology to the pro‐oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. , 1996, The EMBO journal.

[215]  C. Polychronakos,et al.  Parental genomic imprinting of the human IGF2 gene , 1993, Nature Genetics.

[216]  D. Haber,et al.  The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. , 1995, Genes & development.

[217]  R. Morimoto,et al.  The human heat shock protein hsp70 interacts with HSF, the transcription factor that regulates heat shock gene expression. , 1992, Genes & development.

[218]  G. Hammer,et al.  Wilms' Tumor 1 and Dax-1 Modulate the Orphan Nuclear Receptor SF-1 in Sex-Specific Gene Expression , 1998, Cell.

[219]  V. Lalitha,et al.  Rat renal mesenchymal tumor as an experimental model for human congenital mesoblastic nephroma: I. Induction. , 1989, Pediatric pathology.

[220]  J. Cowell,et al.  Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome. , 1992, Human molecular genetics.

[221]  T. Ludwig,et al.  Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Golabi-Behmel syndromes. , 1997, Genes & development.

[222]  Z. Wang,et al.  The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. , 1992, The Journal of biological chemistry.

[223]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[224]  G. Saunders,et al.  The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[225]  M. Sporn,et al.  Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. , 1994, Molecular endocrinology.

[226]  J. Scott,et al.  Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues , 1985, Nature.

[227]  A. Knudson,et al.  Mutation and cancer: a model for Wilms' tumor of the kidney. , 1972, Journal of the National Cancer Institute.

[228]  M. Eccles,et al.  Expression of insulin-like growth factor-II transcripts in Wilms' tumour , 1985, Nature.

[229]  J. Yim,et al.  The Wilms' Tumor 1 Tumor Suppressor Gene Represses Transcription of the Human Telomerase Reverse Transcriptase Gene* , 1999, The Journal of Biological Chemistry.

[230]  J. Milbrandt,et al.  Nuclear Receptor DAX-1 Recruits Nuclear Receptor Corepressor N-CoR to Steroidogenic Factor 1 , 1998, Molecular and Cellular Biology.

[231]  J. Licht,et al.  Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins. , 1997, Biochemical and biophysical research communications.

[232]  J. Wallingford,et al.  Precocious expression of the Wilms' tumor gene xWT1 inhibits embryonic kidney development in Xenopus laevis. , 1998, Developmental biology.

[233]  X. Xia,et al.  Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. , 1993, The Journal of biological chemistry.

[234]  J. Hecksher-Sørensen,et al.  YAC transgenic analysis reveals Wilms' Tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb , 1998, Mechanisms of Development.

[235]  A. Reeve,et al.  Loss of a Harvey ras allele in sporadic Wilms' tumour , 1984, Nature.

[236]  T. Pendergrass.  Congenital anomalies in children with Wilms' Tumor. A new survey , 1976, Cancer.

[237]  A. Jochemsen,et al.  Internal Translation Initiation Generates Novel WT1 Protein Isoforms with Distinct Biological Properties* , 1999, The Journal of Biological Chemistry.

[238]  S. Korsmeyer,et al.  Fulminant metanephric apoptosis and abnormal kidney development in bcl-2-deficient mice. , 1995, The American journal of physiology.

[239]  D. Housman,et al.  An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor , 1990, Cell.

[240]  U. Gullberg,et al.  Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program , 1998, Oncogene.

[241]  A. Brown,et al.  Induction of kidney epithelial morphogenesis by cells expressing Wnt-1. , 1994, Developmental biology.

[242]  P. de Santa Barbara,et al.  Expression and subcellular localization of SF‐1, SOX9, WT1, and AMH proteins during early human testicular development , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[243]  David C. Lee,et al.  Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. , 1999, Development.